Search research articles
Contact Us
Filters
Showing results (631-640 of 709) with videos related to
Page
of 71
Sort By:
Cancer Medicine
|
January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
Geoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncotarget
|
April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
Annals of Translational Medicine
|
August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay
Simon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.
Nature Medicine
|
June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M Gadgeel, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Respiratory Medicine and Research
|
May 23, 2021
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital
C Rolland-Debord, A Canellas, P Choinier, et al.
The Lancet. Infectious Diseases
|
December 1, 2024
Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis
Abhinav Sengupta, Animesh Ray, Ashish Datt Upadhyay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2021
First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
Alexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 71
Search research articles
Search
Showing results (631-640 of 709) with videos related to
Sort By:
Page
of 71
Cancer Medicine
|
January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
Geoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncotarget
|
April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
Annals of Translational Medicine
|
August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay
Simon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.
Nature Medicine
|
June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M Gadgeel, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Respiratory Medicine and Research
|
May 23, 2021
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital
C Rolland-Debord, A Canellas, P Choinier, et al.
The Lancet. Infectious Diseases
|
December 1, 2024
Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis
Abhinav Sengupta, Animesh Ray, Ashish Datt Upadhyay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2021
First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
Alexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 71